Glioblastoma management in the temozolomide era: have we improved outcome? (Q44000206)

28 November 2017

title

Glioblastoma management in the temozolomide era: have we improved outcome? (English)

1 reference

28 November 2017

0 references

1 reference

4

1 reference

28 November 2017

Normand J. Laperriere

8

1 reference

28 November 2017

6

Arjun Sahgal

1 reference

28 November 2017

Zarnie Lwin

1

1 reference

28 November 2017

Derek MacFadden

2

1 reference

28 November 2017

Ahmed Al-Zahrani

3

1 reference

28 November 2017

Barbara Ann Miller

5

1 reference

28 November 2017

Cynthia Menard

7

1 reference

28 November 2017

Warren P Mason

9

1 reference

28 November 2017

publication date

25 August 2013

1 reference

Journal of Neuro-Oncology

28 November 2017

published in

1 reference

28 November 2017

volume

115

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

303-310

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

The impact of enrollment in clinical trials on survival of patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Optimal management of elderly patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Glioma extent of resection and its impact on patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1230-3

A population-based study of glioblastoma multiforme

21 January 2018

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Optimizing Outcomes with Maximal Surgical Resection of Malignant Gliomas

1 reference

12 December 2020

An application of capture-recapture methods to the estimation of completeness of cancer registration

1 reference

12 December 2020

Translating new medical therapies into societal benefit: the role of population-based outcome studies

1 reference

12 December 2020

Comparative-effectiveness research--implications of the Federal Coordinating Council's report

1 reference

12 December 2020

10.1007/S11060-013-1230-3

Identifiers

DOI

1 reference

28 November 2017

1 reference